Karen is the Vice President of Translational Science and executive Program Leader for GNTI-122, our lead program in type 1 diabetes. Prior to joining, Karen led the clinical pharmacology and translational sciences team for cellular and gene therapies at Novartis Pharmaceuticals including both early and stage late development programs. Karen was instrumental in leading the clinical pharmacology strategy for the first cellular therapy (CAR-T) approved in the United States, Europe, and Rest of World, including an Oncology Drug Advisory Committee. She has authored and co-authored numerous seminal papers in the field of cellular and gene therapy. In addition, Karen has led the early development of several ADCs and supported the clinical pharmacology strategies for Kisqali, Afinitor and other established products. Karen received her Doctor of Pharmacy and Master of Science in Pharmaceutical Sciences with a focus on Clinical Pharmacology, from the University of Rhode Island and completed post-doctoral fellowships at the Roswell Park Cancer Institute in Buffalo, the State University of New York Buffalo, and Novartis Pharmaceutical. Karen lives with her husband, Jeff, in New Jersey and enjoys traveling, snowboarding, boating and most importantly keeping up with their extremely energetic and active sons, Clayton, Colton and Bryce.
Karen Mueller, PharmD, MS
VP, Translational Sciences